期刊文献+

核酸疫苗免疫帕金森病小鼠加重黑质炎性反应 被引量:4

The immune inflammatory reaction of DNA vaccine in Parkinson's mouse
下载PDF
导出
摘要 目的:探讨α-突触核蛋白(α-synuclein,α-syn)核酸疫苗免疫帕金森病小鼠后黑质免疫炎性反应的变化。方法:将本实验室成功构建的α-syn核酸疫苗-pVAX1-hα-Syn140用Qiagen试剂盒大量制备α-syn质粒;24只MPTP慢性帕金森病小鼠随机分为3组:实验组、空质粒对照组和PBS对照组,各组小鼠分别肌注pVAX1-hα-Syn140重组质粒,pVAX1空质粒和PBS各100μl,共免疫3次,每次间隔3周,末次免疫后2周,观察小鼠中脑黑质CD11b和TNF-α表达变化。结果:pVAX1-hα-Syn140核酸疫苗免疫组小鼠中脑黑质CD11b表达较对照组增加约36%~37%(P<0.01);TNF-α表达较对照组增加约28%~32%(P<0.01)。结论:pVAX1-hα-Syn140核酸疫苗具有一定的炎性副反应,可在下一步的实验中进行优化,减轻其有害的细胞毒副反应。 Objective:To investigate the immune inflammatory reaction of the ha-syn DNA vaccine in Parkinson's mice. Methods: The constructed hα-syn DNA vaccine was injected intramuscularly to chronic Parkinson's mice three times at three-week interval as the test group. The other two groups of mice were set up as control, including vacant vector plasmids and PBS injected. The changes in expression of CD11b and TNF-α in substantia nigra were visualized two weeks after the third inoculation by immunohistochemistry. The immune inflammatory reactions in chronic Parkinson's mice were assessed by the changed expression of CD11 b and TNF-α in Substantia nigra. Results: Immunization with ha-syn DNA vaccine yielded increase of TNF-α expression and of activated microglia. The CD11b and TNF-α masculine expression of the test group increased by 36%-37% and 28%-32% respectively, showing a significant difference compared with those of control groups. Conclusion: hα-syn DNA vaccine can aggravate immune inflammatory reaction in chronic Parkinson' s mice in some degree.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2009年第6期528-531,共4页 Chinese Journal of Immunology
关键词 帕金森病 Α-突触核蛋白 核酸疫苗 免疫炎性反应 Parkinson' s disease α-synuclein Nucleicacid vaccine Immune inflammatory reaction
  • 相关文献

参考文献9

  • 1Sigurdsson E M.Immunotherapy for conformational diseases[J].Curr Pharm Des,2006;12(20):2569-2585.
  • 2王少君 马宁 彭国光.神经变性构象病的分子机制与治疗策略.第四军医大学学报,2007,28:41-44.
  • 3王少君,王加才,彭国光,罗琴,涂文斌,江思德,徐芙蓉.含CpG基元核酸疫苗免疫慢性MPTP帕金森病小鼠的治疗作用[J].中国实验动物学报,2008,16(3):179-182. 被引量:8
  • 4Dodel R,Hampel H,Deboylu C et al.Human antibodies against amyloidβ peptide:a potential treatment for Alzheimer's disease[J].Ann Neurol,2002;52(2):253-256.
  • 5Orgogozo J M,Gilman S,Dartigues J F et al.Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization[J].Neurology,2003;61(1):46-54.
  • 6Meredith G E,Halliday G M,Toutterdell S.A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease:new insights into Lewy body formation[J].Parkinsonism Relat Disord,2004;10(4):191-202.
  • 7Masliah E,Rockenstein E,Adame A et al.Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease[J].Neuron,2005;46(6):857-868.
  • 8Teismann P,Schulz J B.Cellular patholgoy of Parkinson's disease:Astrocytes,microglia and inflammation[J].Cell Tiss Res,2004;318(1):149-161.
  • 9Mirza B,Hadberg H,Thomsen P et al.The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease[J].Neuroscience,2000;95(2):425-432.

二级参考文献8

  • 1顾凯,刘景晶.核酸疫苗的优化方案[J].药学进展,2005,29(9):385-391. 被引量:3
  • 2高云朝,林祥通.MPTP帕金森病动物模型研究进展[J].中国实验动物学报,2005,13(4):261-265. 被引量:13
  • 3刘树民,张琳,丛树园,于海龙.MPTP对小鼠帕金森病造模条件探讨[J].中国实验动物学报,2007,15(2):146-149. 被引量:14
  • 4McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson' s disease [ J ]. Neurobiol Aging, 2006, 27:530 - 545.
  • 5Sigurdsson EM. lmmunotherapy for conformational diseases[J]. Curr Pharm Des, 2006, 12:2569 - 2585.
  • 6Meredith GE, Halliday GM, Toutterdell S. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson' s disease : new insights into Lewy body formation [J]. Parkinsonism Relat Disord, 2004, 10:191 - 202.
  • 7Lundvig D, Lindersson E, Jensen PH. Pathogenic effects of alphasynuclein aggregation[J]. Brain Res Mol Brain Res, 2005, 134:3- 17.
  • 8Masliah E, Rockenstein E, Adame A, et al. Effects of alphasynuclein immunization in a mouse model of Parkinson' s disease[J]. Neuron, 2005, 46 : 857 - 868.

共引文献7

同被引文献59

  • 1何卿玮,王加才,彭国光,王法祥.pVAX1-IL-4/SYN-B融合质粒的构建及表达[J].免疫学杂志,2009,25(5):588-590. 被引量:8
  • 2Klivenyi P, Gardian G, Calingasan NY, et al. Additive neuroprotec tive effects of creatine and a cyclooxygenase 2 inhibitor against dopa mine depletion in the 1 methyl 4 phenyl-1,2,3,6-tetrahy dropyridine (MPTP) mouse model of Parkinson's disease[J].Mol Neurosci, 2003, 21(3): 191-198.
  • 3Hernan MA, Logroscino G, Garcia Rodriguez LA. Nonsteroidal anti inflammatory drugs and the incidence of Parkinson disease[J].Neurology, 2006, 66(7): 1097 -1099.
  • 4Etminan M, Carleton BC, Samii A. Non steroidal anti inflammatory drug use and the risk of Parkinson disease:a retrospective cohort study[J]. Clin Neurosci, 2008, 15(5):576- 577.
  • 5Rogers J, Mastroeni D, Leonard B, et al. Neuroinflarnmation in Alzheimer's disease and Parkmson's disease: are microglia pathogenic in either disorder[J]? Int Rev Neurobiol, 2007, 82: 235-246.
  • 6Reksidler AB, Lima MM, Zanata SM, et al. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP lesioned rats[J]. Eur J Pharmacol, 2007, 560(2-3) : 163- 175.
  • 7Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthase (cyclooxygenases) 1 and 2[J].Biol Chem, 1996, 271 (52): 33157-33160.
  • 8Lundvig D,Lindersson E, Jensen PH. Pathogenic effects of alphasynuclcin aggregation[J].Brain Res Mol Brain Res, 2005, 134(1): 3-17.
  • 9Masliah E, Roc kenstein E, Adame A, et al. Effects of alpha synuclein immunization in a mouse model of Parkinson's disease[J].Neuron, 2005, 46(6): 857-868.
  • 10Dodel R, Hampel H, Deboylu C, et al. Human antibodies against amyloid peptide: a potential treatment for Alzheimer's disease[J]. Ann Neurol, 2002, 52(2): 253-256.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部